Jul. 23 at 2:01 AM
$SLS $ABBV $GSK $VRTX $MRK AbbVie paid a 49% premium for a drug with zero approvals.
Here's why that's completely rational.
Recently, AbbVie announced it would acquire Apogee Therapeutics for
$10.9 billion, its largest buyout in over five years, according to Reuters.
AbbVie is not alone. In 2026 alone:
→ GSK agreed to buy Nuvalent for
$10.6 billion
→ Vertex is acquiring Crinetics Pharmaceuticals for
$10 billion → Novartis bought Avidity Biosciences for
$12 billion at a 46% premium
This is the new pharma playbook. Internal R&D takes decades, but buying late-stage biotech assets is faster, more predictable, and increasingly the only way to protect revenue against patent cliffs.
A ~49% premium sounds expensive until you compare it to the cost of having no pipeline when your patent runs out.
SLS will keep on running towards its ultimate base upon upcoming Catalysts and Finally bidding war
$240.00+
